The announcement of significant private placement financing typically leads to positive investor sentiment as it reflects confidence in the company's future prospects and financial stability. For Acrivon Therapeutics, this substantial capital infusion is likely to support its research and development activities, potentially leading to breakthroughs or advancements in its product pipeline. This can be seen as a strong endorsement of the company's strategy and potential, likely leading to a positive short-term impact on its stock price.